Villmann Carmen, Oertel Jana, Melzer Nima, Becker Cord-Michael
Institut für Biochemie, Emil-Fischer-Zentrum, Universität Erlangen-Nürnberg, Erlangen, Germany.
J Neurochem. 2009 Nov;111(3):837-47. doi: 10.1111/j.1471-4159.2009.06372.x. Epub 2009 Sep 1.
The human neurological disorder hyperekplexia is frequently caused by recessive and dominant mutations of the glycine receptor alpha1 subunit gene, GLRA1. Dominant forms are mostly attributed to amino acid substitutions within the ion pore or adjacent loops, resulting in altered channel properties. Here, the biogenesis of glycine receptor alpha1 subunit mutants underlying recessive forms of hyperekplexia was analyzed following recombinant expression in HEK293 cells. The alpha1 mutant S231R resulted in a decrease of surface integrated protein, consistent with reduced maximal current values. Decreased maximal currents shown for the recessive alpha1 mutant I244N were associated with protein instability, rather than decreased surface integration. The recessive mutants R252H and R392H encode exchanges of arginine residues delineating the intracellular faces of transmembrane domains. After expression, the mutant R252H was virtually absent from the cell surface, consistent with non-functionality and the importance of the positive charge for membrane integration. Surface expression of R392H was highly reduced, resulting in residual chloride conductance. Independent of the site of the mutation within the alpha1 polypeptide, metabolic radiolabelling and pulse chase studies revealed a shorter half-life of the full-length alpha1 protein for all recessive mutants as compared to the wild-type. Treatment with the proteasome blocker, lactacystin, significantly increased the accumulation of alpha1 mutants in intracellular membranes. These observations indicated that the recessive alpha1 mutants are recognized by the endoplasmatic reticulum control system, and degraded via the proteasome pathway. Thus, the lack of glycinergic inhibition associated with recessive hyperekplexia may be attributed to sequestration of mutant subunits within the endoplasmatic reticulum quality control system.
人类神经系统疾病惊跳症常由甘氨酸受体α1亚基基因(GLRA1)的隐性和显性突变引起。显性形式主要归因于离子孔或相邻环内的氨基酸替换,导致通道特性改变。在此,在HEK293细胞中重组表达后,分析了隐性形式惊跳症潜在的甘氨酸受体α1亚基突变体的生物合成。α1突变体S231R导致表面整合蛋白减少,这与最大电流值降低一致。隐性α1突变体I244N显示的最大电流降低与蛋白质不稳定性有关,而非表面整合减少。隐性突变体R252H和R392H编码跨膜结构域细胞内面精氨酸残基的交换。表达后,突变体R252H在细胞表面几乎不存在,这与无功能以及正电荷对膜整合的重要性一致。R392H的表面表达高度降低,导致残余氯离子传导。与α1多肽内突变位点无关,代谢性放射性标记和脉冲追踪研究表明,与野生型相比,所有隐性突变体的全长α1蛋白半衰期更短。用蛋白酶体阻滞剂乳胞素处理显著增加了α1突变体在细胞内膜中的积累。这些观察结果表明,隐性α1突变体被内质网控制系统识别,并通过蛋白酶体途径降解。因此,与隐性惊跳症相关的甘氨酸能抑制缺乏可能归因于突变亚基在内质网质量控制系统中的隔离。